Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00078-0708-02 00078-0708 Alpelisib PIQRAY 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00078-0708-91 00078-0708 Alpelisib PIQRAY 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0715-02 00078-0715 Alpelisib PIQRAY Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00078-0715-91 00078-0715 Alpelisib PIQRAY Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00078-0716-56 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0716-94 00078-0716 Capmatinib TABRECTA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0811-81 00078-0811 Octreotide Acetate Sandostatin LAR Depot Hormonal Therapy Somatostatin Analog July 22, 2016 In Use
00078-0818-81 00078-0818 Octreotide Acetate Sandostatin LAR Depot Hormonal Therapy Somatostatin Analog July 22, 2016 In Use
00078-0825-81 00078-0825 Octreotide Acetate Sandostatin LAR Depot Hormonal Therapy Somatostatin Analog July 22, 2016 In Use
00078-0846-19 00078-0846 Tisagenlecleucel Kymriah 2000000.0 1/1 Immunotherapy CAR-T CD19 Intravenous Aug. 30, 2017 In Use
00078-0860-01 00078-0860 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0867-14 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0867-42 00078-0867 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-21 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0874-63 00078-0874 Ribociclib Kisqali 200.0 mg/1, 200.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 13, 2017 In Use
00078-0909-61 00078-0909 Ribociclib and letrozole Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal Oral May 4, 2017 In Use
00078-0916-61 00078-0916 letrozole and ribociclib Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal Oral May 4, 2017 In Use
00078-0923-61 00078-0923 letrozole and ribociclib Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal Oral May 4, 2017 In Use
00078-0958-19 00078-0958 tisagenlecleucel KYMRIAH 60000000.0 1/1 Immunotherapy CAR-T CD19 Intravenous May 1, 2018 In Use
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use

Found 10,000 results in 4 milliseconds — Export these results